Fundraising Fox

Shattuck Labs

NASDAQ: STTK

Austin, US · Founded 2016 · Delaware corporation · 4 known investors

Shattuck Labs is a biopharmaceutical company developing a DR3 blocking antibody for the treatment of Inflammatory Bowel Disease and other inflammatory and immune-mediated diseases. Its lead candidate targets the DR3 immune receptor to block TL1A engagement on inflammation-driving immune cells.

Biotech

Founders & leadership

Shattuck Labs was founded in 2016 by Josiah Hornblower.

JH
Josiah HornblowerPresident/CEO

Board

WL
Walter LoewenbaumBoard director

Investors · 4

EcoR1 CapitalSan Francisco
Hatteras Venture PartnersResearch Triangle · $500K – $4M
OrbiMedNew York · $1M – $75M
T. Rowe PricereportedBaltimore

Reported raises · per SEC filings

Form D private placements

$165.4M disclosed across 5 of 6 rounds · 2016–2026

▶$83MraisedJun 2020 · 32 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • G. Walter LoewenbaumDirector
  • Taylor SchreiberExecutive Officer, Director
  • Charles DorranceDirector
  • Victor StoneDirector
  • Josiah HornblowerDirector
  • George GolumbeskiDirector
  • Mike LeeDirector
  • Neil GibsonDirector
  • Tyler BrousDirector
Offering amount
$83M
Amount sold
$83M
First sale
Jun 2020
Incorporated
Corporation, Delaware, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$25.4MraisedFeb 2020 · 71 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Taylor SchreiberExecutive Officer, Director
  • Josiah HornblowerExecutive Officer, Director
  • G. Walter LoewenbaumDirector
  • Tyler BrousDirector
  • Chris HurffDirector
  • Neil GibsonDirector
  • Charles DorranceDirector
  • George GolumbeskiDirector
  • David G. LoweDirector
Offering amount
$50M
Amount sold
$25.4M
First sale
Jan 2020
Incorporated
Corporation, Delaware, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$46.6MraisedMay 2018 · 62 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Taylor SchreiberExecutive Officer, Director
  • Tyler BrousDirector
  • Josiah HornblowerExecutive Officer, Director
  • Charles DorranceDirector
  • Charles GolumbeskiDirector
  • David G. LoweExecutive Officer, Director
  • G. Walter LoewenbaumDirector
  • Neil GibsonDirector
Offering amount
$47.3M
Amount sold
$46.6M
First sale
May 2018
Incorporated
Corporation, Delaware, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$7MraisedApr 2017 · 27 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • G. Walter LoewenbaumDirector
  • Tyler BrousDirector
  • Taylor SchreiberExecutive Officer, Director
  • Neil GibsonDirector
  • David G. LoweDirector
  • Josiah HornblowerExecutive Officer, Director
Offering amount
$7M
Amount sold
$7M
First sale
Mar 2017
Incorporated
Corporation, Delaware, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3.4MraisedAug 2016 · 25 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Walter LoewenbaumDirector
  • Josiah HornblowerExecutive Officer, Director
Offering amount
$3.5M
Amount sold
$3.4M
First sale
Jul 2016
Incorporated
Corporation, Delaware, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 2

by search overlap
Seeking Alpha16 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Dialectic Therapeutics12 shared keywordsDialectic Therapeutics is a clinical-stage biotechnology company developing anti-cancer drugs using its Antiapoptotic Protein Targeted Degradation (APTaD) platform, which induces cancer cells to degrade proteins such as BCL-XL. Its lead candidate, DT2216, is in Phase 1/2 trials for fibrolamellar carcinoma and platinum-resistant ovarian cancer.

Companies competing with Shattuck Labs for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

T. Rowe Price holds 15.3% of Shattuck Labs | STTK SEC Filing - Form SCHEDULE 13G/Astocktitan.net · Aug 2026Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights - BioSpacebiospace.com · Aug 2026Shattuck Labs Q2 Earnings: $15.2M Net Loss | STTK Stock Newsstocktitan.net · Aug 2026Shattuck Labs (NASDAQ: STTK) extends cash runway to 2029 on $54.9M warrant inflow and SL-325 datastocktitan.net · Jun 2026Shattuck Labs raises $54.9M, funds ops into 2029 | STTK Stock Newsstocktitan.net · Jun 2026Shattuck Labs raises $118 million to fight cancer | Raleigh News & Observernewsobserver.com · Jun 2020

Frequently asked questions

What does Shattuck Labs do?
Shattuck Labs is a biopharmaceutical company developing a DR3 blocking antibody for the treatment of Inflammatory Bowel Disease and other inflammatory and immune-mediated diseases. Its lead candidate targets the DR3 immune receptor to block TL1A engagement on inflammation-driving immune cells.
Who founded Shattuck Labs?
Shattuck Labs was founded by Josiah Hornblower in 2016.
Who are Shattuck Labs's investors?
Shattuck Labs's investors include EcoR1 Capital, Hatteras Venture Partners, OrbiMed, T. Rowe Price.
How much funding has Shattuck Labs raised?
Shattuck Labs has disclosed $165.4M raised across 5 of its 6 known rounds.
Where is Shattuck Labs headquartered?
Shattuck Labs is headquartered in Austin, US.